News

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SEATTLE, WA / ACCESS Newswire / April 22, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology ...
Meta Platforms price target lowered to $580 from $730 at Roth Capital
Roth Capital analyst Rohit Kulkarni lowered the firm’s price target on Meta Platforms (META) to $580 from $730 and keeps a Buy rating on the ...